6JU0 Stock Chart & Stats
€0.28
€0.00(0.00%)
At close: 4:00 PM EST
€0.28
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.93M
Enterprise Value€4.96M
Total Cash (Recent Filing)€951.00K
Total Debt (Recent Filing)€412.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 12, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding14,884,328
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.56Price Target Upside4743.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Defined FDA PMA PathwayClear regulatory guidance from FDA that a single well-designed pivotal HF II trial can support a PMA materially reduces regulatory uncertainty. This creates a concrete development path, concentrates resources toward one registrational program, and increases the odds that incremental trial success leads to a definable U.S. approval pathway.
PMDA Support In JapanJapan's PMDA signaling acceptance of existing CardiAMP data and a Shonin path enables a near-term route to market in a major geography. That regulatory alignment plus reimbursement prospects can accelerate commercialization, provide real-world evidence via post-marketing study, and serve as a reference for other markets.
Platform IP & Device Pathways (Helix/Heart3D)A granted patent for Heart3D and defined device regulatory routes for Helix strengthen BioCardia's technology moat and partnership appeal. Durable IP plus a potentially standalone device clearance expand commercial options, enabling platform licensing, device-led partnerships, and multiple revenue pathways beyond a single cell therapy.
Bears Say
Zero/Minimal Revenue & Persistent LossesThe company remains a clinical-stage biotech with no sustainable operating revenue and ongoing large losses. Over the medium term this necessitates continual external financing, dilutes equity value, stresses returns metrics, and limits reinvestment capacity absent successful regulatory or commercial milestones.
Near-Term Cash ShortfallWith cash under $1M and quarterly operational cash use exceeding available funds, the firm faces immediate financing needs. Reliance on periodic raises injects execution and dilution risk, and funding uncertainty can delay trials, regulatory submissions, or partnering discussions critical to long-term commercialization.
Dependence On Pivotal Trial & Enrollment RiskU.S. approval hinges on completing the HF II pivotal trial; slow center activation and resource-constrained enrollment raise execution risk. Protracted enrollment delays or underpowered analyses would extend timelines and financing needs, jeopardizing the intended regulatory pathway and commercial launch timing.
BioCardia News
6JU0 FAQ
What was Biocardia’s price range in the past 12 months?
Biocardia lowest stock price was €0.28 and its highest was €0.32 in the past 12 months.
What is Biocardia’s market cap?
Biocardia’s market cap is €11.93M.
When is Biocardia’s upcoming earnings report date?
Biocardia’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Biocardia’s earnings last quarter?
Biocardia released its earnings results on May 15, 2026. The company reported -€0.184 earnings per share for the quarter, missing the consensus estimate of -€0.145 by -€0.039.
Is Biocardia overvalued?
According to Wall Street analysts Biocardia’s price is currently Undervalued.
Does Biocardia pay dividends?
Biocardia does not currently pay dividends.
What is Biocardia’s EPS estimate?
Biocardia’s EPS estimate is -0.16.
How many shares outstanding does Biocardia have?
Biocardia has 14,884,328 shares outstanding.
What happened to Biocardia’s price movement after its last earnings report?
Biocardia reported an EPS of -€0.184 in its last earnings report, missing expectations of -€0.145. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biocardia?
Currently, no hedge funds are holding shares in DE:6JU0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocardia
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
6JU0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and regulatory progress—statistically significant blinded echocardiography results, constructive PMDA guidance in Japan, favorable FDA engagement, device pathway clarity for Helix, and reduced operating expenses. However, these positives are tempered by an immediate funding shortfall (cash of $951k), the need to complete an additional pivotal trial for U.S. approval (PMA pathway) and enrollment/resource risks for the HF II study. Management plans near-term financing in Q2 to fund the Japan submission and trial enrollment, but execution and funding risk remain material.View all DE:6JU0 earnings summaries6JU0 Stock 12 Month Forecast
Average Price Target
€13.56
▲(4743.36% Upside)
Technical Analysis
Options Prices
Currently, No data available
---